STOCKS TELEGRAPH

Tag: NASDAQ: MTP

  • Midatech Pharma (NASDAQ: MTP) Reveals MTX110 Phase I DIPG Study Results

    Midatech Pharma (NASDAQ: MTP) Reveals MTX110 Phase I DIPG Study Results

    Midatech Pharma Plc (NASDAQ: MTP) has announced today the promising headline results from Phase I study in patients with Diffuse Intrinsic Pontine Glioma (DIPG). The biotechnology company has revealed the results at the University of California, San Francisco (UCSF). A total of seven patients were enrolled in this UCSF study. They all were newly diagnosed with Diffuse Intrinsic Pontine Glioma (DIPG).

    Before the start of MTX110 treatment, all the patients were given the focal external beam radiation therapy for four to 14 weeks. MTX110 was injected directly into the tumor via a micro-catheter using convection-enhanced delivery (CED) with gadolinium-enhanced intra-operative MRI to guide and track drug distribution to the tumor. All the patients were given the 12 cycles of treatment every four to eight weeks.

    The level of doses was increased with the increase in the level of tolerance at a concentration of 30μM MTX110 and then with higher drug concentrations of 60μM and 90μM as the sixth and seventh dose increments, respectively were given to the patients.

    The primary purpose of the Phase II study is to determine the dosage level which is to be used to study the safety and efficacy of MTX110 in patients with DIPG. The study data showed that the dosage of  60μM and 90μM of MTX110 is proven to be very useful in treating patients in the course of 12 infusions in Phase II. The dosage level depends on the tolerance level of the patient.

    Midatech Pharma Plc (NASDAQ: MTP) shares were trading down -6.54% at $2.00 during the trading session of Friday. Midatech Pharma Plc (MTP) share price went from a low point around $0.86 to briefly over $7.52 in the past 52 weeks, though shares have since pulled back to $2.00. MTP market cap has remained high, hitting $25.23 million at the time of writing.

    The median overall survival based on Kaplan Meier analysis was 26.06 months and overall survival at 12 months (OS12) was 71.4% (five of seven patients alive) at the interim cut-off date (30th September 2020). As per the study, three patients remained alive and are continuously monitored.

    UCSF’s study endpoint was not a survival rate and the date hasn’t revealed the effect of MTX1010 on the survival rate in patients with Diffuse Intrinsic Pontine Glioma (DIPG). The given Phase II trial is anticipated to analyze overall survival at 12 months as the primary endpoint in 19 evaluable patients. Diffuse Intrinsic Pontine Glioma (DIPG) is a primary brain tumor starting in the middle of the brain stem, is diffusely invading. This tumor cannot be surgically removed.

     

  • Stocks to Watch as Markets Await Retail Data

    Stocks to Watch as Markets Await Retail Data

    The markets are headed for a weak start to the day, as investors await retail sales data.  It is widely expected that July data will show a slowdown compared to June data.  The numbers are expected to show an increase of 2.1% compared to 7.5% in June. The slowdown is an indicator of the depletion of the bailout money that had driven the V-shaped recovery that the markets experienced in June.

    According to the Chief U.S Economist at Deutsche Bank, Matt Luzzetti, the end of these benefits puts a significant risk to consumer spending especially the low-income bracket. Amidst the risks posed by an end to the benefits, the markets are watching the impasse between Democrats and Republicans on an economic bailout. While Trump already signed an executive order on the economy, it is not enough to support a full-blown economic recovery.

    Despite the weakness in the economy as reflected in the anticipated retail data. There are stocks that recorded significant gains pre-market. If the data comes out positive and beats market expectations, these pre-market gainers could close the week in the money. Some of the biggest gainers ahead of markets are as below.

    Voxeljet AG [NYSE: VJET]

    Voxeljet AG looks set to start the day in gains. This comes after the company reported Q2 results. The company reported that total revenues in Q2 ir dropped by 22.5%.  It also reported that gross profit margins dropped slightly from 30.2% in Q2 of 2019 to 25.9%. The CEO Dr. Ingo Ederer stated that a few months ago, it got a large individual order for its 3D printers from a top U.S Electric car maker.  However, he added that the company’s revenues were hit by the COVID-19 pandemic. Nonetheless, the company announced that it had managed to improve its cash position through its partnership with the European Investment Bank. He added that they were looking forward to a stronger second half of the year.

    Taiwan Liposome Company Ltd [NASDAQ: TLC]

    This is another top performer this morning and is up by 95% pre-market. This follows the company’s announcement that it had submitted an IND for TLC19, an inhalable Liposomal Hydroxychloroquine in the treatment of COVID-19.  Given the global anticipation for a COVID-19 vaccine/cure, this stock is likely to rally all through the day on the strength of these new.

    Midatech Pharma Plc [NASDAQ: MTP]

    Midatech Pharma PLC is another top performer this morning and is a key stock to watch today.  This follows the company’s announcement of its registration statement with regards to a 12,695,445 share resale. This is likely to keep the stock active all day and close the week on a higher note.